已收盤 10-24 16:00:00 美东时间
-0.150
-1.45%
今日重点评级关注:摩根大通:维持Cogent Biosciences"超配"评级,目标价从30美元升至44美元;Piper Sandler:维持Vital Energy"中性"评级,目标价从16美元升至30美元
10-22 10:10
Canaccord Genuity analyst John Newman maintains Delcath Systems (NASDAQ:DCTH) with a Buy and maintains $21 price target.
10-22 00:29
今日重点评级关注:Maxim Group:维持Rani Therapeutics Hldgs"买入"评级,目标价从5美元升至10美元;韦德布什:维持Corbus Pharmaceuticals"跑赢大市"评级,目标价从31美元升至38美元
10-21 18:13
美股周一早盘,肿瘤药物开发企业Delcath Systems(DCTH)股价下跌10%,此前该公司报告第三季度营收2050万美元,略低于预期,并下调了全年指...
10-20 21:50
The latest update is out from Delcath Systems ( ($DCTH) ). On October 18, 2025,...
10-20 18:31
Preliminary Third Quarter Financial Results (unaudited)Total CHEMOSAT and HEPZATO KIT revenue of approximately $20.5 millionHEPZATO KIT revenue of $19.2 millionCHEMOSAT revenue of $1.3 millionGross margins expected to be
10-20 15:52
Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the acceptance of an oral presentation on results from the
09-23 04:03
An update from Delcath Systems ( ($DCTH) ) is now available. On August 12, 2025...
08-16 04:52
Delcath Systems shares are trading higher after the company reported better-tha...
08-06 20:35
Companies Reporting Before The Bell • Lineage (NASDAQ:LINE) is likely to report...
08-06 16:33